Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor

详细信息    查看全文

• 作者：Dorien Groenendaal-van de Meent ; Martin den Adel…
• 刊名：Clinical Drug Investigation
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：36
• 期：9
• 页码：743-751
• 全文大小：473 KB
• 刊物主题：Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine;
• 出版者：Springer International Publishing
• ISSN：1179-1918
• 卷排序：36

文摘

Background and ObjectiveRoxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor in phase III development for the treatment of anaemia associated with chronic kidney disease. This study evaluated the effects of moderate hepatic impairment on roxadustat pharmacokinetics, pharmacodynamics and tolerability.